AIM ImmunoTech Advances Ampligen in Pancreatic Cancer with Phase 2 Study
Event summary
- AIM ImmunoTech released a CEO Corner video discussing Ampligen's potential in pancreatic cancer on September 9, 2026.
- The Phase 2 DURIPANC study is evaluating Ampligen in combination with AstraZeneca's durvalumab as maintenance therapy.
- Ampligen aims to reshape the tumor microenvironment and enhance checkpoint inhibition.
- Primary endpoint analyses and biomarker evaluations are expected in the DURIPANC study.
The big picture
AIM ImmunoTech is focusing on pancreatic cancer, a disease known for its immunosuppressive tumor microenvironment. The company's strategy with Ampligen aims to address this biological barrier by activating innate immunity and making tumors more responsive to checkpoint inhibition. The ongoing Phase 2 DURIPANC study is a critical step in evaluating Ampligen's potential in this challenging indication.
What we're watching
- Clinical Efficacy
- How Ampligen's ability to reshape the tumor microenvironment will affect its efficacy in combination with checkpoint inhibitors.
- Regulatory Strategy
- Whether AIM can leverage DURIPANC data to inform a potential pivotal development program.
- Biomarker Development
- The pace at which biomarker research will identify patients most likely to benefit from Ampligen.
Related topics